Advertisement
Canada markets closed
  • S&P/TSX

    22,346.76
    -121.40 (-0.54%)
     
  • S&P 500

    5,307.01
    -14.40 (-0.27%)
     
  • DOW

    39,671.04
    -201.95 (-0.51%)
     
  • CAD/USD

    0.7306
    +0.0000 (+0.00%)
     
  • CRUDE OIL

    77.00
    -0.57 (-0.73%)
     
  • Bitcoin CAD

    95,070.56
    -846.19 (-0.88%)
     
  • CMC Crypto 200

    1,512.92
    -13.50 (-0.88%)
     
  • GOLD FUTURES

    2,374.90
    -18.00 (-0.75%)
     
  • RUSSELL 2000

    2,081.71
    -16.65 (-0.79%)
     
  • 10-Yr Bond

    4.4340
    +0.0200 (+0.45%)
     
  • NASDAQ futures

    18,905.50
    +118.75 (+0.63%)
     
  • VOLATILITY

    12.29
    +0.43 (+3.63%)
     
  • FTSE

    8,370.33
    -46.12 (-0.55%)
     
  • NIKKEI 225

    38,898.11
    +281.01 (+0.73%)
     
  • CAD/EUR

    0.6744
    -0.0001 (-0.01%)
     

FibroGen First Quarter 2024 Earnings: Beats Expectations

FibroGen (NASDAQ:FGEN) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$55.9m (up 55% from 1Q 2023).

  • Net loss: US$32.9m (loss narrowed by 57% from 1Q 2023).

  • US$0.33 loss per share (improved from US$0.81 loss in 1Q 2023).

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

FibroGen Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 53%. Earnings per share (EPS) also surpassed analyst estimates by 38%.

Looking ahead, revenue is forecast to grow 1.9% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

ADVERTISEMENT

Performance of the American Biotechs industry.

The company's shares are up 22% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 5 warning signs for FibroGen (of which 3 make us uncomfortable!) you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.